Picture of InBioGen Co logo

101140 InBioGen Co Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
IndustrialsHighly SpeculativeMicro Cap

Annual cashflow statement for InBioGen Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line13,124-45,07894,125-119,68718,857
Depreciation
Amortisation
Non-Cash Items-13,98241,006-101,259107,843-23,597
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-3,225-4,405-1,052-1,0992,465
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-3,828-8,033-7,069-11,505-1,051
Capital Expenditures-416-971-2,402-331-331
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-54,626-4,895-38,035-15,594138
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-55,042-5,866-40,437-15,925-193
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities66,29514,97061,54313,568-1,957
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash7,4251,07214,038-13,862-3,201